Over 30 years in drug development at Bristol-Myers Squibb Co., served as Head of Development and led approval of four products
After joining CynosBio, led the acquisition of marketing approval and insurance coverage for Sacracy in 2022

Master of Pharmacy

Joined the company in 2024 and is responsible for overseeing corporate strategy, capital strategy, business development, and international expansion.
Previously, led IPOs, global fundraising, and cross-border M&A at a pioneering advanced medical technology company.
Also, as a venture capitalist, invested in and supported the growth of approximately 30 life science startups.

MBA/CPA

Former investment banker with more than 100 M&A and capital raising advisory projects in foreign firm and has extensive experience in accounting, taxation, and business management of startups as a CPA. He promotes strategic finance from both “offensive” and “defensive” perspectives.

MBA/CPA

this is a photo of Masahiro Go, CTO Head of Chemistry, Manufacturing and Control
Engaged in basic biology (developmental genetics) research at universities and basic and applied regenerative medicine research at companies. Responsible for the Kobe Medical Industry Promotion Organization (FBRI), where he has led the R & D and manufacturing of our company's flagship regenerative medicine products for more than 15 years

Doctor of Science

He has spent 30 years in sales and marketing for Bristol-Myers Squibb Co., Ltd. He has been responsible for liver and oncology marketing. Made significant contributions to the growth strategy through the market introduction of new drugs and the expansion of their indications.

After conducting research activities at Fujitsu Laboratories, he was involved in the founding of several venture companies, including life sciences, and gained management experience. Later, he joined our company as a founding member, and supported the founding of R & D projects and business plans. Currently, he is widely involved in business promotion.

Served as CFO and COO at HEROZ, Inc., where he led the company’s listing on the Tokyo Stock Exchange.
Prior to that, worked in the Investment Banking Division of Goldman Sachs, primarily engaged in corporate fundraising activities.
Appointed as Outside Director of the Company in 2022.

Doctor of Business Administration(DBA)

After serving as General Manager of the Hepatitis Division at AbbVie GK, was appointed Advisor to the company in 2022.
Prior to that, held positions including Executive Corporate Officer and Head of the New Drug Division, as well as Senior Executive Corporate Officer and Head of the Liver, Hematology, and Oncology Division at Bristol-Myers Squibb.
Appointed as Outside Director of the Company in 2024.

Before joining the Company, served as General Manager of Marketing Planning and General Manager of Affiliated Companies at Eisai Co., Ltd., and later as Full-time Audit & Supervisory Board Member at EA Pharma Co., Ltd.
Prior to that, was engaged in prescription drug marketing and M&A at Eisai.
In the field of auditing, served as Secretary of a subcommittee of the Japan Audit & Supervisory Board Members Association, possessing deep expertise in Audit and Supervisory Committee operations.

Appointed Full-time Audit & Supervisory Board Member of JMDC Inc. in 2016, and Director & Audit and Supervisory Committee Member of the same company in 2019.
Appointed Audit & Supervisory Board Member of the Company in 2023, and Director & Audit and Supervisory Committee Member in 2024.

After working at Deloitte Touche Tohmatsu LLC, founded AGRI Law & Accounting Office.
Appointed Audit & Supervisory Board Member of the Company in 2023, and Director & Audit and Supervisory Committee Member in 2024.

Lawer / CPA

After gaining experience in accounting, consulting, and audit at Mitsubishi UFJ Bank, EY ShinNihon LLC, and various consulting firms, founded Ōka Tax Corporation.
Appointed Audit & Supervisory Board Member of the Company in 2023, and Director & Audit and Supervisory Committee Member in 2024.

CPA